Results 201 to 210 of about 891,020 (314)

<i>LILRB1</i> and <i>LILRB2</i> genomics and transcriptomics in macaque and baboon species: polymorphism, diversification, and extensive alternative splicing. [PDF]

Front Immunol
de Groot NG, de Groot N, Heijmans CMC, de Vos-Rouweler AJM, van der Wiel MKH, Bruijnesteijn J.   +5 more
europepmc   +1 more source

Hereditary spherocytosis with band 3 deficiency. Association with a nonsense mutation of the band 3 gene (allele Lyon), and aggravation by a low-expression allele occurring in trans (allele Genas) [PDF]

, 1996
Nicole Alloisio, Philippe Maillet, Geneviève Carré, Pascale Texier, Agnès Vallier, Faouzi Baklouti, N Philippe, J. Delaunay   +7 more
openalex   +1 more source

Cleavage‐Resistant CYLD Protects Against Autoimmune Hepatitis

Advanced Science, EarlyView.
Proteolytic cleavage of the deubiquitinase CYLD emerges as a critical driver of autoimmune hepatitis. TNFα‐induced CYLD loss in macrophages amplifies S100A9‐triggered MAPK activation, leading to excessive chemokine production and hepatic inflammation. Pharmacological inhibition of MEK signaling effectively attenuates experimental disease, highlighting ...
Han Liu, Chen Su, Jianling Liu, Mingyan Xing, Xiaoxia Wu, Lingxia Wang, Xiaoming Zhao, Hanwen Zhang, YangYang Xie, YangYang Wang, Hong Li, Yu Li, Ming Li, Haibing Zhang   +13 more
wiley   +1 more source

Frequency of HLA class I and II in an admixed Brazilian population with psoriasis. [PDF]

An Bras Dermatol
Sampaio AL, Romana-Souza B, Monteiro H, Nogueira JS, Secco DA, Cantos GCD, Monte-Alto-Costa A, Cassia F, Carneiro S, Azulay-Abulafia L, Porto LC.   +10 more
europepmc   +1 more source

POPULATION CONSEQUENCES OF NON‐MENDELIAN SEGREGATION AMONG MULTIPLE ALLELES [PDF]

, 1970
Daniel L. Hartl
openalex   +1 more source

Dual Targeting of Mutant p53 and SNRPD2 via Engineered Exosomes Modulates Alternative Splicing to Suppress Ovarian Cancer

Advanced Science, EarlyView.
Mutant p53 drives oncogenic splicing to promote the progression of ovarian cancer by partnering with the spliceosome factor SNRPD2. Therefore, it is engineered iRGD‐exosomes to co‐deliver siRNAs against both targets. This approach restored tumor‐suppressive mRNA isoforms, effectively enhanced sensitivity to cisplatin, and ultimately blocked tumor ...
Wei Zhao, Qian Hao, Yu Gan, Jing Tong, Xiaodan Chen, Shuran Tan, Ruiwen Ruan, Yingdan Huang, Mingming Cao, Jun Deng, Tao Han, Getao Shi, Bo Gao, Yu Zhang, Xiang Zhou   +14 more
wiley   +1 more source

Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele. [PDF]

Cancer
DiLeo M, Oglesby S, Leung CH, Pauken KE, Farooq S, Haydu LE, Kubicki SL, Martinez R, Welborn M, Zahiruddin S, Zou J, Cao K, Patel AB.   +12 more
europepmc   +1 more source

Restriction fragment alleles of the rabbit IGHG genes with reference to the rabbit IGHGCH2 or e locus polymorphism [PDF]

, 2002
Pedro J. Esteves, Paulo C. Alves, Nuno Ferrand, Wessel van der Loo   +3 more
openalex   +1 more source

Discovery of a Novel DNMT1 Inhibitor with Improved Efficacy in Treating β‐Thalassemia

Advanced Science, EarlyView.
Context of Research: β‐thalassemia affects millions worldwide. DNMT inhibitors are effective HbF‐inducers that benefit patients with β‐thalassemia. Existing DNMT inhibitors are not approved for β‐thalassemia treatment due to dose‐limiting toxicity.What We Find: DMT207 traps DNMT1 into helix‐kinked inactive conformation and enhances its interaction with
Yijie Shen, Jiale Wei, Shibing Tang, Dongliang Wu, Liangyi Zong, Shuyuan Ma, Qing Xiong, Ruijie Gong, Siyuan Xu, Chuxuan Peng, Qin Feng, Songchen Liu, Qitong Liu, Yuhua Ye, Quan Zhao, Cheng Luo, Peng Huang, Zhihai Li, Xiangqian Kong, Xianjiang Lan   +19 more
wiley   +1 more source

TCR2HLA: Calibrated inference of HLA genotypes from TCR repertoires enables identification of immunologically relevant metaclonotypes. [PDF]

PLoS Comput Biol
Mayer-Blackwell K, Minervina A, Pogorelyy M, Rawat P, Shapiro MR, Peters LD, Ford ES, Posgai AL, Vegesana K, Minot S, Koelle DM, Greiff V, Bradley P, Brusko TM, Thomas PG, Fiore-Gartland A.   +15 more
europepmc   +1 more source